SUSRF OTC
Surgical Science Sweden AB
1W: +0.0%
1M: +0.0%
3M: +30.0%
YTD: +52.5%
1Y: -46.5%
3Y: -67.8%
$5.20
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$990M
+12.0% ▲
5Y CAGR: +56.7%
Gross Profit
$575M
-3.8% ▼
5Y CAGR: +45.5%
Operating Income
$109M
-24.7% ▼
5Y CAGR: +40.3%
Net Income
$67M
-49.4% ▼
5Y CAGR: +33.7%
EPS (Diluted)
$1.29
-50.0% ▼
5Y CAGR: +23.4%
EBITDA
$192M
+13.1% ▲
5Y CAGR: +44.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $367M | $803M | $883M | $884M | $990M |
| YoY Growth | +250.0% | +118.8% | +10.0% | +0.1% | +12.0% |
| Cost of Revenue | $101M | $271M | $270M | $286M | $414M |
| Gross Profit | $266M | $532M | $613M | $598M | $575M |
| Gross Margin | 72.5% | 66.2% | 69.4% | 67.6% | 58.1% |
| R&D Expenses | $66M | $173M | $182M | $196M | $191M |
| SG&A Expenses | $146M | $202M | $240M | $252M | $276M |
| Operating Expenses | $209M | $369M | $424M | $454M | $467M |
| Operating Income | $89M | $163M | $189M | $144M | $109M |
| Operating Margin | 24.2% | 20.3% | 21.4% | 16.3% | 11.0% |
| Interest Expense | $23M | $1M | $15M | $0 | $0 |
| Income Before Tax | $66M | $208M | $268M | $158M | $100M |
| Tax Expense | -$20M | $20M | $34M | $26M | $33M |
| Net Income | $86M | $188M | $234M | $132M | $67M |
| Net Margin | 23.5% | 23.4% | 26.5% | 14.9% | 6.7% |
| EPS (Diluted) | $2.02 | $3.69 | $4.59 | $2.58 | $1.29 |
| EBITDA | $115M | $271M | $214M | $170M | $192M |
| Shares Outstanding | 43M | 51M | 51M | 51M | 51M |